12/10
07:07 am
inab
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting [Yahoo! Finance]
Medium
Report
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting [Yahoo! Finance]
12/10
07:00 am
inab
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
High
Report
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
12/2
07:00 am
inab
IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
High
Report
IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
11/26
08:00 am
inab
IN8bio, Inc. (NASDAQ: INAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
IN8bio, Inc. (NASDAQ: INAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
11/25
07:19 am
inab
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting [Yahoo! Finance]
Medium
Report
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting [Yahoo! Finance]
11/25
07:00 am
inab
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
Medium
Report
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
11/13
09:10 am
inab
IN8bio, Inc. (NASDAQ: INAB) had its price target lowered by analysts at HC Wainwright from $12.50 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
IN8bio, Inc. (NASDAQ: INAB) had its price target lowered by analysts at HC Wainwright from $12.50 to $8.00. They now have a "buy" rating on the stock.
11/12
04:30 pm
inab
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Medium
Report
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
11/12
04:26 pm
inab
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Medium
Report
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
11/12
07:00 am
inab
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
High
Report
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
11/5
09:00 am
inab
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
High
Report
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting